Ethris GmbH

Based in Planegg just outside Munich, Germany, Ethris was founded by Dr. Carsten Rudolph and Prof. Christian Plank to establish messenger RNA as a new drug modality. As an mRNA pioneer, we are applying our unique, proprietary SNIM® RNA platform to drive a range of drug candidates into proof-of-concept and the clinic and our goal is to develop therapeutics to treat patients with respiratory disorders and beyond.

 
We maintain a first-mover advantage with a differentiated nebulization technology for inhaled delivery of mRNA-containing nanoparticles and are approaching in vivo proof-of-concept for generating mRNA encoded therapeutic antibodies against COVID-19 in the lung and our pipeline of immuno-modulation and mRNA-based protein replacement therapy programs for several pulmonary disease indications.